Navigation Links
New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies
Date:10/16/2007

SCOTTSDALE, Ariz., Oct. 16 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Anxiety & Depression," physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.

"There have been some notable developments in the use of antipsychotics, and special emphasis on new classes -- including CRF and NK antagonists," according to Jeff Berk, MedPredict President. "The thesis of this panel is that there are two types of new drug launches that will be successful in the next five years. The first is augmentation strategies to SSRIs. Today this includes the use of low dose quetiapine. This time frame should also see the approval of the first NK and CRF antagonists." According to this report, monotherapy strategies will find a home mostly in the primary care setting after failure of a generic SSRI. In the community setting, safety will trump efficacy, and a parity claim with an improved side effect profile will win out.

The report also discusses the role of genomics, endophenotypes and biomarkers in the development of pharmacotherapies for depression.

Drugs/Companies mentioned in this report include: Effexor (venlafaxine; Wyeth), Lexapro (escitalopram; Forest), Pristiq (o-desmethylvenlafaxine; Wyeth), Cymbalta (duloxetine; Lilly), Wellbutrin (bupropion; GlaxoSmithKline), Valdoxan (agomelatine; Novartis/Servier), bifeprunox (Wyeth/Solvay/ Lundbeck), Seroquel (quietiapine; AstraZeneca), amibegron (Sanofi-Aventis), GSK-561679 (GSK), Pexacerfont (BMS-562086; Bristol-Myers Squibb), ONO-2333Ms (Ono), casopitant (GlaxoSmithKline), saredutant (Sanofi-Aventis), esmirtazapine (Organon / Schering-Plough), Nemifitide (Tetragenix), SSR241586 (Sanofi-Aventis), and many others.

This report can be purchased by contacting MedPredict. Members of the media may request an interview.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. No harm in reducing prenatal check up to 3 - 6 times says WHO report
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Report on the Safety and Effectiveness of Melatonin supplements
6. WHO report asks for improved healthcare for mother and child
7. Research reports that c-section deliveries are rising
8. Jharkhand reports 13,000 Malaria cases
9. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
10. Experts Insist That Neonatal Herpes Be Reported Regularly
11. Uganda Reports Failure To Contain Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: